U.S., Dec. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07276581) titled 'A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis' on Dec. 01.
Brief Summary: Phase II study in participants with moderately-to-severely active rheumatoid Arthritis (RA) to evaluate efficacy and safety of AZD1163.
Study Start Date: Dec. 15
Study Type: INTERVENTIONAL
Condition:
Rheumatoid Arthritis
Intervention:
DRUG: AZD1163
Participants will receive SC injection of one of three different doses of AZD1163 in combination with SoC (csDMARD or TNFi +/- csDMARDSoC) until Week 24.
OTHER: Placebo
Participants will receive SC injection of placebo matched to AZD1163 in combination with ...